Waldemar Fryze

Randomized phase III study 306

Gregory L. Krauss, José M. Serratosa, Vicente Villanueva et al. · Neurology · 2012 · 429 citations

Medicine, Pharmacology, Pharmacotherapy +15

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Scott E. Kasner, Balakumar Swaminathan, Pablo M. Lavados et al. · The Lancet Neurology · 2018 · 178 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Global Impact of COVID-19 on Stroke Care and IV Thrombolysis

Raul G. Nogueira, Muhammad M. Qureshi, Mohamad Abdalkader et al. · Neurology · 2021 · 154 citations · Full text

Life Sciences, Health Sciences, Global Health +13